This Stock Under $2 Could Go to $20 (And STILL Be a SCREAMING BUY)
Analysts predict earnings will soar more than 320% this year...Possibly as much as 500%!

Discover the last opportunity that could still rocket skyward in THIS market.

Click Here to Discover Details on the Shocking Less Than $2 Stock.

VRPX Insider Trading (Virpax Pharmaceuticals)

Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): $115,536.75
Insider Selling (Last 12 Months): $0.00

Virpax Pharmaceuticals Insider Trading History Chart

This chart shows the insider buying and selling history at Virpax Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Virpax Pharmaceuticals Share Price & Price History

Current Price: $1.30
Price Change: Price Decrease of -0.045 (-3.36%)
As of 05/16/2022 04:03 PM ET

This chart shows the closing price history over time for VRPX up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
Warning: The Last Value Play Gone After August?
In this market...There's ONE STOCK (priced at just under $2) that could be $20 and STILL be a bargain. It brought in more income – including equity sales - in the last 12 months than Disney, Square or Tesla.

But a key announcement in August could send this stock rocketing skyward.
Get the Details Now.

Virpax Pharmaceuticals Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/22/2021Jerrold SendrowDirectorBuy3,900$3.92$15,288.00View SEC Filing Icon  
11/18/2021Anthony P. MackCEOBuy25,125$3.99$100,248.75View SEC Filing Icon  
2/17/2021Thani JambulingamDirectorBuy100$7.16$716.00100View SEC Filing Icon  
See Full Table
Renowned Economist issues startling prediction | America's Future
According to former Goldman Sachs executive, Nomi Prins…

Americans who are hoping for a ‘return to normal’ are going to be shocked when they see what happens next in America.

She says, “If you’re betting your job, savings, or retirement accounts on a return to ‘normal’ you’re about to be left behind by a brand-new crisis few see coming.”
Click here now to see America’s next crisis.

SEC Filings (Institutional Ownership Changes) for Virpax Pharmaceuticals (NASDAQ:VRPX)

18.90% of Virpax Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at VRPX by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Virpax Pharmaceuticals Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
5/13/2022Renaissance Technologies LLC156,600$0.35M0.0%N/A1.337%Search for SEC Filing on Google Icon
5/13/2022Vanguard Group Inc.341,977$0.76M0.0%+4.5%2.918%Search for SEC Filing on Google Icon
5/13/2022Warberg Asset Management LLC17,710$39K0.0%N/A0.151%Search for SEC Filing on Google Icon
5/12/2022Citigroup Inc.12,179$27K0.0%N/A0.104%Search for SEC Filing on Google Icon
2/14/2022Citadel Advisors LLC98,046$0.34M0.0%N/A0.837%Search for SEC Filing on Google Icon
2/11/2022Geode Capital Management LLC47,671$0.16M0.0%+374.6%0.407%Search for SEC Filing on Google Icon
2/8/2022Northern Trust Corp15,221$52K0.0%N/A0.130%Search for SEC Filing on Google Icon
11/17/2021Altium Capital Management LP271,846$1.31M0.3%N/A2.320%Search for SEC Filing on Google Icon
11/16/2021National Asset Management Inc.18,600$90K0.0%N/A0.159%Search for SEC Filing on Google Icon
11/16/2021Two Sigma Investments LP25,715$0.12M0.0%N/A0.220%Search for SEC Filing on Google Icon
11/12/2021Geode Capital Management LLC10,045$48K0.0%N/A0.086%Search for SEC Filing on Google Icon
11/2/2021Cambridge Investment Research Advisors Inc.19,420$93K0.0%N/A0.166%Search for SEC Filing on Google Icon
9/17/2021Virtu Financial LLC23,625$0.11M0.0%N/A0.468%Search for SEC Filing on Google Icon
8/16/2021Sabby Management LLC154,737$0.70M0.1%-22.6%3.120%Search for SEC Filing on Google Icon
8/12/2021Saltoro Capital LP17,615$80K0.0%-34.8%0.355%Search for SEC Filing on Google Icon
5/14/2021HN Saltoro Capital LP27,000$0.13M0.0%N/A0.546%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Virpax Pharmaceuticals logo
Virpax Pharmaceuticals, Inc., a preclinical stage biopharmaceutical company, develops and manufactures non-opioid and non-addictive pharmaceutical products using drug delivery systems for pain management. The company offers products, such as Epoladerm, a diclofenac metered-dose spray film for acute musculoskeletal pain; Probudur (LBL100), long-acting bupivacaine liposomal gel for postoperative pain management; OSF200 for chronic osteoarthritis of the knee; and NES100 (Envelta), an exogenous enkephalin intranasal spray for acute and chronic pain. It also develops PES200 for the management of post-traumatic stress disorder; and MMS019 high-density molecular masking spray to prevent or reduce the risk or the intensity of viral infections in humans, including influenza and SARS-CoV-2 (Covid-19). Virpax Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Berwyn, Pennsylvania.
Read More on Virpax Pharmaceuticals

Today's Range

Now: $1.30
Low: $1.27
High: $1.35

50 Day Range

MA: $1.98
Low: $1.33
High: $2.39

52 Week Range

Now: $1.30
Low: $1.25
High: $36.00


14,677 shs

Average Volume

193,816 shs

Market Capitalization

$15.17 million

P/E Ratio


Dividend Yield




Who are the company insiders with the largest holdings of Virpax Pharmaceuticals?

Virpax Pharmaceuticals' top insider investors include:
  1. Thani Jambulingam (Director)
  2. Anthony P Mack (CEO)
  3. Jerrold Sendrow (Director)
Learn More about top insider investors at Virpax Pharmaceuticals.

Who are the major institutional investors of Virpax Pharmaceuticals?

Virpax Pharmaceuticals' top institutional shareholders include:
  1. Vanguard Group Inc. — 2.92%
  2. Renaissance Technologies LLC — 1.34%
  3. Warberg Asset Management LLC — 0.15%
  4. Citigroup Inc. — 0.10%
Learn More about top institutional investors of Virpax Pharmaceuticals stock.

Which institutional investors are buying Virpax Pharmaceuticals stock?

Within the previous quarter, VRPX stock was acquired by institutional investors including:
  1. Renaissance Technologies LLC
  2. Warberg Asset Management LLC
  3. Vanguard Group Inc.
  4. Citigroup Inc.
Within the last year, these company insiders have bought Virpax Pharmaceuticals stock:
  1. Thani Jambulingam (Director)
  2. Anthony P Mack (CEO)
  3. Jerrold Sendrow (Director)
Learn More investors buying Virpax Pharmaceuticals stock.
Investor Alert: Argentina Loaded With "White Gold" Opportunity
Experts expect the global lithium market to grow by 500% due to the explosion of electric vehicles and green energy. And one small-cap company just snagged a large lithium deposit in a renowned South American location.
Read about this once-in-a-lifetime opportunity